RecruitingPhase 3NCT06914609
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome
Sponsor
Ionis Pharmaceuticals, Inc.
Enrollment
158 participants
Start Date
Jun 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Eligibility
Min Age: 2 YearsMax Age: 50 Years
Inclusion Criteria6
- The participants caregiver(s)/ legally authorized representative must have given written informed consent and any authorizations required by local law and be able to comply with all study requirements.
- Medically stable and can undergo sedation and/or general anesthesia without intubation.
- Male or female between 2 and lesser than or equal to (≤)50 years of age, depending on specific cohort, at the time of the in-clinic Screening visit.
- Participant has a clinical diagnosis of Angelman syndrome (AS) with molecular confirmation of either Ubiquitin-protein ligase E3A (UBE3A) deletion or UBE3A mutation.
- Currently receiving stable doses of concomitant medications typically prescribed for AS, such as anti-epileptic medication, behavioral management medications, sleep medications, gabapentin, cannabidiol, and special diets, supplements, or nutritional support for at least 8 weeks prior to the Baseline visit.
- Legally authorized representative/caregiver(s) agree(s) not to post any of the participant's personal medical data or information related to the study on any website or social media site (e.g., Facebook, Instagram, X (formerly Twitter), YouTube, TikTok, etc.) from the time of enrollment until they are notified that the study is completed.
Exclusion Criteria6
- Must not have any clinically significant abnormalities in medical history (e.g., major surgery within 3 months of screening), or on physical examination for which treatment with an antisense oligonucleotide (ASO) would be contraindicated or which, in the opinion of the Principal Investigator (PI), could confound the results of this study.
- Known brain or spinal disease that would interfere with the lumbar puncture (LP) procedure, cerebrospinal fluid (CSF) circulation, or presence of other factors would affect the safety of the LP procedure.
- Must not have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.
- Must not have any laboratory abnormalities or any other clinically significant abnormalities that would, as assessed by the Investigator, at screening or Baseline, render a participant unsuitable for inclusion.
- Previous treatment with an oligonucleotide (including small interfering ribonucleic acid (RNA) \[siRNA\], ASOs) gene therapy or gene editing. This exclusion criterion does not apply to approved nucleic acid-based vaccines, including mRNA vaccines, which are allowed.
- Has molecular confirmation of AS due to paternal uniparental disomy, imprinting center defect, or mosaic findings.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGION582
ION582 will be administered by IT injection.
DRUGPlacebo
ION582 matching placebo will be administered by IT injection.
Locations(36)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06914609
Related Trials
A Natural History Study of Angelman Syndrome
NCT074171371 location
Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman Syndrome
NCT067377181 location
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT0715725422 locations
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
NCT071818373 locations
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
NCT0594557620 locations